If you are 18 years old or older and are a man who has sex with men, or a transgender woman who has sex with men, you may be eligible for a study.
The main purpose of this clinical research trial is to see if cabotegravir, an antiretroviral medication can prevent infection with HIV in persons at high risk for HIV infection.
The study will last 1.5 – 3 years and you may be eligible if you are:
• 18 years of age or older
• HIV negative
• Sex assigned at birth was male
• Gender - male or trans female
• Have sex with men
This study is a double blind study – all participants receive active medication but neither they nor the study staff will be aware of which medication they are getting. All participants will receive an injection every 2 months and oral tablets that are taken once daily.
Participants will be compensated for their time and will receive regular HIV testing and counseling, condoms and lubricant.
A full description of the study is available at https://clinicaltrials.gov/ct2/show/NCT02720094
If you are interested in this study – please contact Project WISH to arrange for a phone screen at 312-413-5897
The Principal Investigator is Richard M. Novak MD, Chief of Infectious Diseases, Department of Medicine, University of Illinois at Chicago.
CSB Clinical Sciences Building
General public/Campus community/Faculty/Staff/Students/Alumni/Prospective students